Editor's note:“Monthly Bullish and Bearish Stocks in Hong Kong and the US”The section closely follows market trends, takes stock of the monthly performance of the Hong Kong and US stock markets, helps Niuyou sort through the hot sectors, strong individual stocks, and major news of the month to find profitable investment topics.
In October, the three major indices of Hong Kong stocks fluctuated and declined after rising at the beginning of the month. As of October 30, the market closed.The Hang Seng Index fell 2.26% to close at 17,468 points throughout the month; the State-owned Enterprises Index fell 3.06% to close at 5985 points; and the Hang Seng Technology Index fell 1.69% to close at 3,798 points.
CICC pointed out that the Hong Kong stock market is at the “bottom of policy,” and investors will need a certain amount of time to absorb recent progress before gradually transitioning to “sentiment bottom” and “market bottom.” More sustained upward potential may require continued policy support to create a virtuous cycle and a positive upward trend.
Privatization premium is as high as 1.14 times!$HAITONG INT'L (00665.HK)$Stock prices rose 98% this month, topping the list of Hong Kong stock gains this month.
On October 6, Haitong International received a proposal from the majority shareholder Haitong Securities to privatize the company through an agreed arrangement. The cash price per share was HK$1.52, a premium of about 114.09% over the closing price of HK$0.71 before the stock was suspended. Furthermore, according to the transaction announcement recently disclosed by Haitong International, since the privatization was announced, the four executives have bought a total of nearly one million shares.
The popularity of pharmaceutical stocks has escalated!$LAEKNA-B (02105.HK)$It reached a new high in the listing,$HANSOH PHARMA (03692.HK)$The stock price soared by more than 40%.$ALPHAMAB-B (09966.HK)$,$INNOVENT BIO (01801.HK)$,$JUNSHI BIO (01877.HK)$Equity shares have followed suit.
As the popularity of research and development in emerging fields such as GLP-1 diet drugs, AD, and NASH continues to rise, and domestic innovative drugs continue to achieve excellent results, the pharmaceutical sector rebounded overall in October. Anxin Securities pointed out that from an investment perspective, there are currently positive factors in the innovative pharmaceutical industry: (1) low valuations have allocation value; (2) short-term catalysts for health insurance negotiations; and (3) the Fed's interest rate hike is nearing an end.
The consumer electronics sector is picking up,$SUNNY OPTICAL (02382.HK)$,$COWELL (01415.HK)$Both climbed higher, rising 26% and 24% respectively.
The e-commerce Double Eleven promotion window opened, and press conferences such as Huawei and Apple were held intensively, catalyzing the consumer electronics and mobile phone industry chain. The agency pointed out that the overall valuation level of the consumer electronics sector is low, and there is plenty of room for repair. Based on the quarterly improvement in the performance of the industrial chain, demand is expected to gradually break out of the trough.
The performance was impressive, and after that, it received a lot of acclaim from major groups!$GWMOTOR (02333.HK)$Earnings in a single quarter reached a record high, surging more than 7% in a single day after the results.
In the third quarter of this year, Great Wall Motor's revenue reached 49.532 billion yuan, up 32.63% year on year; net profit was 3.635 billion yuan, up 41.94% year on year, all exceeding market expectations. Net profit deducted from non-return accounts in a single quarter increased by 34.1% year-on-year to 3,058 billion yuan, a record high for the same period. CICC raised Great Wall Motor's target price by 16% to HK$14.5 to maintain its “outperform the industry” rating. Komo raised its target price significantly from HK$9 to HK$16, and the rating was raised from neutral to increased.
On the other hand, the weakest performing stocks this month are as follows:
edit/new